ILMN completed its acquisition of SomaLogic from Standard BioTools while divesting GRAIL, marking a strategic pivot toward proteomics amid new tariff-related uncertainties.
The company is repositioning its portfolio by exiting the cancer screening business (GRAIL divestiture) while entering proteomics through the SomaLogic acquisition, suggesting a focus on expanding beyond genomics. However, management has added new risk disclosures around U.S. tariffs beginning in April 2025, indicating potential cost pressures and supply chain challenges ahead.
ILMN's financial position improved meaningfully with operating cash flow growing 29% to $1.1 billion and current assets expanding 20% to $3.3 billion, reflecting stronger operational performance. The company reduced R&D spending by 17% to $967 million, likely reflecting cost discipline amid the business transition. Overall, the balance sheet strengthened with stockholders' equity rising 15% to $2.7 billion, though the market value held by non-affiliates declined from $14.7 billion to $9.2 billion, indicating share price pressure during the reporting period.
Operating cash flow grew 28.9% — strong conversion of earnings to cash, healthy business fundamentals.
Current assets grew 19.8% — improving short-term liquidity or inventory/receivables build.
R&D spending cut 17.3% — could signal cost discipline or concerning reduction in innovation investment.
Receivables grew 16.2% — monitor days sales outstanding for collection efficiency.
Equity base grew 14.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →